Performance of Redox Active and Chelatable Iron Assays to Determine Labile Iron Release From Intravenous Iron Formulations

Emerging data from global markets outside the United States, where many generic iron sucrose formulations are available, have revealed that non‐US generic intravenous (i.v.) iron formulations may have iron release profiles that differ from the reference listed drug (RLD). The first generic i.v. iron...

Descripción completa

Detalles Bibliográficos
Autores principales: Pai, AB, Meyer, DE, Bales, BC, Cotero, VE, Pai, MP, Zheng, N, Jiang, W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5421824/
https://www.ncbi.nlm.nih.gov/pubmed/28160427
http://dx.doi.org/10.1111/cts.12443

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5421824/
https://www.ncbi.nlm.nih.gov/pubmed/28160427
http://dx.doi.org/10.1111/cts.12443

Ejemplares similares